Abstract |
One hundred Gram-positive bacteremia organisms from five important genus groups were tested against 10 newer beta-lactams. Ceftazidime was significantly less active (50% of strains at less than or equal to 8 micrograms/ml) compared to other cephalosporins. The penems (FCE-22101 and HRE-664) and imipenem were each superior to the cephalosporins with 92-93% inhibition of strains. A novel fused co- drug of fleroxacin and desacetyl- cefotaxime, Ro 23-9424, was 100% effective against these Gram-positive pathogens at less than or equal to 8 micrograms/ml. Several of these compounds should receive consideration for clinical trials for empiric therapy among neutropenic patient infections where Gram-positive pathogens may be more prevalent.
|
Authors | R N Jones, A L Barry |
Journal | Diagnostic microbiology and infectious disease
(Diagn Microbiol Infect Dis)
1989 Mar-Apr
Vol. 12
Issue 2
Pg. 143-7
ISSN: 0732-8893 [Print] United States |
PMID | 2666014
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Anti-Infective Agents
- Fluoroquinolones
- Ro-23-9424
- Ciprofloxacin
- Ceftazidime
- Cefotaxime
- Fleroxacin
|
Topics |
- Anti-Bacterial Agents
(pharmacology)
- Anti-Infective Agents
(pharmacology)
- Cefotaxime
(analogs & derivatives, pharmacology)
- Ceftazidime
(pharmacology)
- Ciprofloxacin
(analogs & derivatives, pharmacology)
- Fleroxacin
(analogs & derivatives)
- Fluoroquinolones
- Gram-Positive Bacteria
(drug effects, isolation & purification)
- Humans
- Microbial Sensitivity Tests
- Sepsis
(microbiology)
|